{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-316995","form_type":"8-K","ticker":"SRPT","cik":"0000873303","company_name":"Sarepta Therapeutics, Inc.","filed_at":"2026-07-27T13:08:03+00:00","discovered_at":"2026-07-27T13:09:00.221536+00:00","generated_at":"2026-07-27T13:09:06.915605+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Sarepta names Michael Severino CEO effective July 28; Ingram retires","bullets":["Michael Severino appointed CEO effective July 28, 2026; succeeds Doug Ingram who retires.","Severino receives $1.18M base salary, 110% target bonus, and $35M sign-on equity grant.","Ingram to serve as consultant through Dec 2026 at $15k/month consulting fee.","Severino previously CEO of Tessera Therapeutics and Vice Chairman/President at AbbVie.","Severino also appointed to Sarepta's Board of Directors as Class I director."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-316995","json":"https://secwatch.observer/filing/0001193125-26-316995.json","markdown":"https://secwatch.observer/filing/0001193125-26-316995.md","text":"https://secwatch.observer/filing/0001193125-26-316995.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/873303/000119312526316995/0001193125-26-316995-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/873303/000119312526316995/d101719d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-07-27T13:09:06.915605+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2cd5d375e9","claim":"Michael Severino was appointed as Class I director at Sarepta Therapeutics, Inc..","evidence_excerpt":"Also on July 23, 2026, the Board appointed Dr. Severino, effective as of the Effective Date, as a Class I director","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/873303/000119312526316995/0001193125-26-316995-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Class I director"}],"fact_type":"executive_change"},{"claim_id":"2f7cd0ba43","claim":"Michael Severino was appointed as Chief Executive Officer at Sarepta Therapeutics, Inc..","evidence_excerpt":"On July 23, 2026, the Board of Directors (the “Board”) of Sarepta Therapeutics, Inc. (the “Company”) appointed Michael Severino, M.D. as Chief Executive Officer of the Company, effective July 28, 2026","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/873303/000119312526316995/0001193125-26-316995-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"9fbd47638b","claim":"Douglas Ingram departed as Chief Executive Officer at Sarepta Therapeutics, Inc..","evidence_excerpt":"Mr. Ingram will depart from his position as Chief Executive Officer and a member of the Board as of the Effective Date.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/873303/000119312526316995/0001193125-26-316995-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"depart"},{"label":"Role","value":"Chief Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"d07db31f95","claim":"Douglas Ingram departed as member of the Board at Sarepta Therapeutics, Inc..","evidence_excerpt":"Mr. Ingram will depart from his position as Chief Executive Officer and a member of the Board as of the Effective Date.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/873303/000119312526316995/0001193125-26-316995-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"depart"},{"label":"Role","value":"member of the Board"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}